First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the three months ended September 30, 2009.

Net loss for the three month period ended September 30, 2009 was $189,296, or $0.01 per share, compared with a net loss of $1,181,406, or $0.06 per share, for the three month period ended September 30, 2008. This decrease in net loss was primarily the result of an increase in non-cash income related to the change in fair value of a warrant liability, which was partially offset by an increase in operating expenses and non-cash expenses associated with the outstanding convertible notes and a decrease in revenue and interest income.

Quarterly and Recent Highlights

• Senesco presented pre-clinical stability and biological activity data on multiple myeloma drug candidate SNS-01 at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference
• Certain Senesco insiders entered into definitive stock purchase agreements to purchase all of the convertible debentures, warrants and common stock which are held by Stanford Venture Capital Holdings, Inc. and/or Stanford International Bank, Ltd.
• Senesco entered into separate funding agreements, totaling $1.7 million, with Partlet Holdings Ltd., certain members of Senesco's Board of Directors and certain accredited investors, including Cato Holding Company, which is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization currently assisting Senesco with its SNS-01 development program; with the emphasis on initiating a Phase I clinical trial for multiple myeloma
• Richard Dondero, Vice President of Research & Development at Senesco, delivered the Company's corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference

"SNS-01 continues to demonstrate potential as a possible treatment for multiple myeloma, most recently being the subject of a poster presentation at one of the most important oncology conferences of the year, the annual AACR-NCI-EORTC Conference," said Jack Van Hulst, President and Chief Executive Officer of Senesco.

The Company did not record any revenue for the three month period ended September 30, 2009. Total revenues of $200,000 for the three month period ended September 30, 2008 consisted of a milestone payment in connection with an agricultural license agreement.

Research and development expenses during the three month period ended September 30, 2009 were $575,291, compared with $504,386 during the three month period ended September 30, 2008, an increase of 14.1%. This increase was primarily a result of an $89,000 loss on the extinguishment of debt in connection with the issuance of common stock and warrants to Cato Holding Company in exchange for debt that was owed by Senesco to Cato Research Ltd. in the amount of $175,000, which was slightly offset by decrease in the cost of the research performed at the University of Waterloo as a result of the stronger U.S. dollar against the Canadian dollar.

General and administrative expenses were $494,955 for the three month period ended September 30, 2009, compared with $529,865 during the three month period ended September 30, 2008, a decrease of 6.6%. This decrease was due primarily to a $34,000 decrease in stock based compensation, and a $20,000 decrease in professional fees, which were a result of a decrease in legal and accounting fees related to the review of our securities filings. These decreases were slightly offset by a $15,000 increase in director fees associated with an increase in the size of the board of directors from eight to ten.

At September 30, 2009, Senesco had cash, cash equivalents and investments of $1,075,295, and working capital of $1,596,515, which the Company estimates will cover its expenses for approximately the next three months from September 30, 2009.